CD4 and Alzheimer disease: Kitajima et al. proposed a mouse model to define a possible future cure for AD, suggesting that the blockade of the receptor of TSLP (TSLPR) in CD4+ lymphocytes interrupts the chronic phase of inflammation (but not the acute phase), which was proven using knock-out mice for this surface receptor [59].